Abstract
| Original language | English |
|---|---|
| Journal | Disease Markers |
| DOIs | |
| Publication status | Published - 1 Jan 2016 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Molecular Biology
- Genetics
- Clinical Biochemistry
- Biochemistry, medical
Cite this
}
Detection of autoantibodies to vascular endothelial growth factor Receptor-3 in bile duct ligated rats and correlations with a panel of traditional markers of liver diseases. / Duval, Florent; Cruz-Vega, Delia Elva; González-Gamboa, Ivonne; González-Garza, María Teresa; Ponz, Fernando; Sánchez, Flora; Alarcón-Galván, Gabriela; Moreno-Cuevas, Jorge E.
In: Disease Markers, 01.01.2016.Research output: Contribution to journal › Article
TY - JOUR
T1 - Detection of autoantibodies to vascular endothelial growth factor Receptor-3 in bile duct ligated rats and correlations with a panel of traditional markers of liver diseases
AU - Duval, Florent
AU - Cruz-Vega, Delia Elva
AU - González-Gamboa, Ivonne
AU - González-Garza, María Teresa
AU - Ponz, Fernando
AU - Sánchez, Flora
AU - Alarcón-Galván, Gabriela
AU - Moreno-Cuevas, Jorge E.
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Copyright © 2016 Florent Duval et al. There is a need for new noninvasive biomarkers (NIBMs) able to assess cholestasis and fibrosis in chronic cholestatic liver diseases (CCLDs). Tumorigenesis can arise from CCLDs. Therefore, autoantibodies to tumor-associated antigens (TAA) may be early produced in response to abnormal self-antigen expression caused by cholestatic injury. Vascular endothelial growth factor receptor-3 (VEGFR-3) has TAA potential since it is involved in cholangiocytes and lymphatic vessels proliferations during CCLDs. This study aims to detect autoantibodies directed at VEGFR-3 during bile duct ligation- (BDL-) induced cholestatic injury in rat sera and investigate whether they could be associated with traditional markers of liver damage, cholestasis, and fibrosis. An ELISA was performed to detect anti-VEGFR-3 autoantibodies in sera of rats with different degree of liver injury and results were correlated with aminotransferases, total bilirubin, and the relative fibrotic area. Mean absorbances of anti-VEGFR-3 autoantibodies were significantly increased from week one to week five after BDL. The highest correlation was observed with total bilirubin (R2= 0.8450, P = 3.04e - 12). In conclusion, anti-VEGFR-3 autoantibodies are early produced during BDL-induced cholestatic injury, and they are closely related to cholestasis, suggesting the potential of anti-VEGFR-3 autoantibodies as NIBMs of cholestasis in CCLDs and justifying the need for further investigations in patients with CCLD.
AB - Copyright © 2016 Florent Duval et al. There is a need for new noninvasive biomarkers (NIBMs) able to assess cholestasis and fibrosis in chronic cholestatic liver diseases (CCLDs). Tumorigenesis can arise from CCLDs. Therefore, autoantibodies to tumor-associated antigens (TAA) may be early produced in response to abnormal self-antigen expression caused by cholestatic injury. Vascular endothelial growth factor receptor-3 (VEGFR-3) has TAA potential since it is involved in cholangiocytes and lymphatic vessels proliferations during CCLDs. This study aims to detect autoantibodies directed at VEGFR-3 during bile duct ligation- (BDL-) induced cholestatic injury in rat sera and investigate whether they could be associated with traditional markers of liver damage, cholestasis, and fibrosis. An ELISA was performed to detect anti-VEGFR-3 autoantibodies in sera of rats with different degree of liver injury and results were correlated with aminotransferases, total bilirubin, and the relative fibrotic area. Mean absorbances of anti-VEGFR-3 autoantibodies were significantly increased from week one to week five after BDL. The highest correlation was observed with total bilirubin (R2= 0.8450, P = 3.04e - 12). In conclusion, anti-VEGFR-3 autoantibodies are early produced during BDL-induced cholestatic injury, and they are closely related to cholestasis, suggesting the potential of anti-VEGFR-3 autoantibodies as NIBMs of cholestasis in CCLDs and justifying the need for further investigations in patients with CCLD.
U2 - 10.1155/2016/6597970
DO - 10.1155/2016/6597970
M3 - Article
JO - Disease Markers
JF - Disease Markers
SN - 0278-0240
ER -